SKYE BIOSCIENCE DL -,001 Aktie

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).» Mehr auf globenewswire.com

• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, presented a clinical pharmacokinetic (“PK”) and pharmacodynamic (“PD”) model that underscores the fundamental relationship between biodistribution and efficacy of CB1 inhibitors at the annual European Congress on Obesity meeting. This model demonstrated that achieving strong peripheral CB1 inhibition is sufficient to achieve efficacy, including weight loss.» Mehr auf globenewswire.com

Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive Officer Chris Twitty - Chief Scientific Officer Kaitlyn Arsenault - Chief Financial Officer Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Conference Call Participants Jay Olson - Oppenheimer Albert Lowe - Craig-Hallum Ted Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Andy Hsieh - William Blair Jon Wolleben - Citizens JMP Bernie Hertel Hello, and thank you all for participating in today's call. Joining me today is Punit Dhillon, Skye's President and CEO; Chris Twitty, CSO, and Kaitlyn Arsenault, Skye's CFO.» Mehr auf seekingalpha.com